InBriefs January 20, 2021 ION537 will be evaluated at MD Anderson in a Phase 1 study of patients with liver and head and neck cancers Read More July 10, 2020 New England Journal of Medicine: Results of Phase 1/2 study of tofersen, an antisense oligonucleotide, demonstrate proof-of-concept and proof-of-biology of the Ionis-created therapy to treat SOD1 familial ALS Read More June 17, 2020 Lancet Gastroenterology and Hepatology: innovative antisense therapy shows potential to be safe and efficacious for the treatment of NAFLD and NASH Read More May 6, 2020 Lancet Neurology: Teens and adults on SPINRAZA® showed clinically meaningful improvement in motor function Read More March 30, 2020 Ionis Statement on COVID-19 Read More February 27, 2020 Ionis and partner highlight tominersen (formerly known as IONIS-HTTRx and RG6042) data at annual Huntington’s disease drug discovery conference Read More
January 20, 2021 ION537 will be evaluated at MD Anderson in a Phase 1 study of patients with liver and head and neck cancers Read More
July 10, 2020 New England Journal of Medicine: Results of Phase 1/2 study of tofersen, an antisense oligonucleotide, demonstrate proof-of-concept and proof-of-biology of the Ionis-created therapy to treat SOD1 familial ALS Read More
June 17, 2020 Lancet Gastroenterology and Hepatology: innovative antisense therapy shows potential to be safe and efficacious for the treatment of NAFLD and NASH Read More
May 6, 2020 Lancet Neurology: Teens and adults on SPINRAZA® showed clinically meaningful improvement in motor function Read More
February 27, 2020 Ionis and partner highlight tominersen (formerly known as IONIS-HTTRx and RG6042) data at annual Huntington’s disease drug discovery conference Read More